Skip to main content
Caplight Logo









ThirtyFiveBio

ThirtyFiveBio

Private
AbingdonHealthcare & Life Scienceshttps://www.thirtyfivebio.com/

Last Round

VC Round

Apr 15, 2025

Total Funding Raised

$21.44M

Company Overview

ThirtyFiveBio is a biotechnology company developing first-in-class small-molecule inhibitors of G protein-coupled receptor 35 (GPR35) to treat severe gastrointestinal diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologydrug discoverysmall molecule inhibitorsGPR35 antagonistsulcerative colitisinflammatory bowel diseaseIBDgut epithelial shieldpreclinical researchbiotech startupgastroenterologytherapeutic developmentdrug pipelinebiotech R&D

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ThirtyFiveBio Comparables

Compare ThirtyFiveBio with similar companies based on industry and business-model similarity.

ThirtyFiveBio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Nxera Pharma
73%
Bristol Myers Squibb
71%
N-Zyme Biomedical
70%

ThirtyFiveBio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundApr 15, 2025
GrantJul 2, 2024
GrantSep 13, 2023

ThirtyFiveBio Investors

Notable investors and investment history

ThirtyFiveBio investors
InvestorRounds
Innovate UKGrant
AbbVie VenturesVC Round
Innovate UKGrant
Canaan PartnersSeed, VC Round
Mayewell CapitalVC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 15, 2025

    Raised $3.56M led by Canaan Partners

ThirtyFiveBio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

ThirtyFiveBio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about ThirtyFiveBio's valuation, stock price, and market status.

Firmographic Details

HeadquartersAbingdon
Employee Range15
Year Founded2021
Last FundingApr 15, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?